(firstQuint)Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients.

 The efficacy and safety will be compared between Chiglitazar and placebo after treatment of 24 weeks.

 The long term efficacy and safety of Chiglitazar will be evaluated after 52 weeks treatment.

.

 Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients@highlight

The purpose of this study is to evaluate the efficacy and safety of Chiglitazar, compare with placebo.

